Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
Type:
Grant
Filed:
December 14, 2018
Date of Patent:
August 22, 2023
Assignee:
NMD PHARMA A/S
Inventors:
Thomas Holm Pedersen, Lars J. S. Knutsen, Nicholas M. Kelly, Martin Broch-Lips, Claus Elsborg Olesen, Marc Labelle, Ole Bækgaard Nielsen, Rajesh Kumar
Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel. The compounds include phenoxy propanoic acid, phenoxy propanoate, and phenoxy butanoate compounds.
Type:
Grant
Filed:
December 14, 2017
Date of Patent:
February 28, 2023
Assignee:
NMD PHARMA A/S
Inventors:
Lars J. S. Knutsen, Thomas Holm Pedersen, Claus Elsborg Olesen, Marc A. Labelle, Paul Brian Little, Martin E. Cooper, Neerja Saraswat, Dastagiri Dudekula, Rafiq A. Taj
Abstract: The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.
Type:
Application
Filed:
June 19, 2020
Publication date:
December 8, 2022
Applicant:
NMD PHARMA A/S
Inventors:
Lars J.S. KNUTSEN, Nicholas KELLY, Martin Brandhøj SKOV, Anders RIISAGER, Neerja SARASWAT
Abstract: The present disclosure relates to compounds of Formula I: suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
Type:
Application
Filed:
June 19, 2020
Publication date:
September 29, 2022
Applicant:
NMD PHARMA A/S
Inventors:
Nicholas KELLY, Lars J.S. KNUTSEN, Daniel Paul COTTON
Abstract: The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.
Type:
Application
Filed:
June 19, 2020
Publication date:
September 1, 2022
Applicant:
NMD PHARMA A/S
Inventors:
Lars J.S. KNUTSEN, Martin BROCH-LIPS, Martin E COOPER, Marc LABELLE, Thomas Holm PEDERSEN, Dastagiri DUDEKULA, Neerja SARASWAT, Rafiq A TAJ
Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
Type:
Grant
Filed:
December 14, 2017
Date of Patent:
October 19, 2021
Assignee:
NMD PHARMA A/S
Inventors:
Lars J. S. Knutsen, Thomas Holm Pedersen, Martin Broch-Lipps, Claus Elsborg Olesen, Marc Labelle, Ole Baekgaard Nielsen
Abstract: The present invention relates to compositions comprising compounds for use in treating, ameliorating and/or preventing neuromuscular disorders. The compounds as defined herein preferably inhibit the ClC-1 ion channel. The invention further relates to methods of treating, preventing and/or ameliorating neuromuscular disorders, by administering said composition to a person in need thereof.
Type:
Grant
Filed:
June 15, 2016
Date of Patent:
March 2, 2021
Assignee:
NMD PHARMA A/S
Inventors:
Thomas Holm Pedersen, Martin Broch-Lips, Claus Elsborg Olesen, Marc Labelle, Ole Bækgaard Nielsen
Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
Type:
Grant
Filed:
December 14, 2017
Date of Patent:
August 20, 2019
Assignee:
NMD PHARMA A/S
Inventors:
Lars J. S. Knutsen, Martin E. Cooper, Andrew W. Brown
Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
Type:
Application
Filed:
December 14, 2018
Publication date:
June 20, 2019
Applicant:
NMD PHARMA A/S
Inventors:
Lars J.S. Knutsen, Nicholas M. Kelly, Thomas Holm Pedersen, Martin E. Cooper, Andrew W. Brown
Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
Type:
Application
Filed:
December 14, 2018
Publication date:
June 20, 2019
Applicant:
NMD PHARMA A/S
Inventors:
Thomas Holm Pedersen, Lars J.S. Knutsen, Nicholas M. Kelly, Martin Broch-Lips, Claus Elsborg Olesen, Marc Labelle, Ole Bækgaard Nielsen, Rajesh Kumar
Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
Type:
Application
Filed:
December 14, 2018
Publication date:
June 20, 2019
Applicant:
NMD PHARMA A/S
Inventors:
Lars J.S. Knutsen, Nicholas M. Kelly, Thomas Holm Pedersen, Claus Elsborg Olesen, Marc Labelle, Paul Brian Little, Martin E. Cooper, Neerja Saraswat, Dastagiri Dudekula, Rafiq A. Taj